Compare NEA & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEA | OCUL |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.4B |
| IPO Year | N/A | 2014 |
| Metric | NEA | OCUL |
|---|---|---|
| Price | $11.57 | $12.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $22.56 |
| AVG Volume (30 Days) | 803.4K | ★ 3.9M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,783,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.20 | $5.79 |
| 52 Week High | $11.37 | $16.44 |
| Indicator | NEA | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 45.98 |
| Support Level | $11.45 | $11.15 |
| Resistance Level | $11.65 | $14.64 |
| Average True Range (ATR) | 0.09 | 0.90 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 47.16 | 26.44 |
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.